<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Treatment Options - CancerInsight SG</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <nav class="main-nav">
        <div class="nav-brand">
            <span class="nav-logo">üè•</span>
            <span class="nav-title">CancerInsight SG</span>
        </div>
        <ul class="nav-links">
            <li><a href="index.html">Cancer Types</a></li>
            <li><a href="assessment.html">Health Profile</a></li>
            <li><a href="survival.html">Survival Rates</a></li>
            <li><a href="treatment.html" class="active">Treatments</a></li>
            <li><a href="costs.html">Costs</a></li>
            <li><a href="resources.html">Resources</a></li>
        </ul>
    </nav>

    <main class="page-content">
        <div class="page-header">
            <h1>Treatment Options</h1>
            <p>Evidence-based treatment protocols from NCCN Clinical Practice Guidelines 2024</p>
        </div>

        <div class="alert alert-warning">
            <strong>Medical Disclaimer:</strong> Treatment recommendations vary based on individual factors.
            Always consult your oncologist for personalized treatment plans. Information based on NCCN Guidelines Version 2024.
        </div>

        <!-- Cancer Type Selector -->
        <div class="filter-section">
            <div class="filter-group">
                <label for="cancer-select">Select Cancer Type:</label>
                <select id="cancer-select" class="form-select">
                    <option value="breast">Breast Cancer</option>
                    <option value="colorectal">Colorectal Cancer</option>
                    <option value="lung">Lung Cancer</option>
                    <option value="prostate">Prostate Cancer</option>
                    <option value="liver">Liver Cancer (HCC)</option>
                    <option value="stomach">Stomach Cancer</option>
                    <option value="ovary">Ovarian Cancer</option>
                    <option value="uterus">Uterine Cancer</option>
                    <option value="cervix">Cervical Cancer</option>
                    <option value="thyroid">Thyroid Cancer</option>
                    <option value="lymphoma">Lymphoma</option>
                    <option value="kidney">Kidney Cancer</option>
                    <option value="bladder">Bladder Cancer</option>
                    <option value="pancreas">Pancreatic Cancer</option>
                    <option value="nasopharyngeal">Nasopharyngeal Cancer</option>
                </select>
            </div>
        </div>

        <!-- Treatment Content Sections -->
        <div id="treatment-content">

            <!-- BREAST CANCER -->
            <section id="breast-treatment" class="treatment-section">
                <h2>Breast Cancer Treatment</h2>

                <div class="treatment-overview">
                    <div class="stat-card">
                        <div class="stat-value">89%</div>
                        <div class="stat-label">5-Year Survival (All Stages)</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">99%</div>
                        <div class="stat-label">Localized Stage</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">86%</div>
                        <div class="stat-label">Regional Stage</div>
                    </div>
                </div>

                <div class="tabs">
                    <button class="tab-btn active" data-tab="breast-first">First-Line Treatment</button>
                    <button class="tab-btn" data-tab="breast-second">Second-Line / Progression</button>
                    <button class="tab-btn" data-tab="breast-drugs">Drug Reference</button>
                </div>

                <div id="breast-first" class="tab-content active">
                    <h3>First-Line Treatment by Stage</h3>

                    <div class="accordion">
                        <div class="accordion-item">
                            <button class="accordion-header">Stage I-II (Early Stage)</button>
                            <div class="accordion-content">
                                <h4>Surgery Options</h4>
                                <ul>
                                    <li><strong>Lumpectomy (Breast-Conserving Surgery)</strong> - Removes tumor with margin of healthy tissue</li>
                                    <li><strong>Mastectomy</strong> - Total removal of breast tissue</li>
                                    <li><strong>Sentinel Lymph Node Biopsy</strong> - Check for spread</li>
                                </ul>

                                <h4>Adjuvant Therapy</h4>
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Subtype</th>
                                            <th>Treatment</th>
                                            <th>Duration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>HR+/HER2-</td>
                                            <td>Endocrine therapy (Tamoxifen or Aromatase Inhibitor)</td>
                                            <td>5-10 years</td>
                                        </tr>
                                        <tr>
                                            <td>HER2+</td>
                                            <td>Trastuzumab + Chemotherapy</td>
                                            <td>1 year (Trastuzumab)</td>
                                        </tr>
                                        <tr>
                                            <td>Triple Negative</td>
                                            <td>Chemotherapy (AC-T or TC regimen)</td>
                                            <td>4-6 months</td>
                                        </tr>
                                    </tbody>
                                </table>

                                <h4>Radiation</h4>
                                <p>Required after lumpectomy; 3-6 weeks of daily treatment</p>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage III (Locally Advanced)</button>
                            <div class="accordion-content">
                                <h4>Neoadjuvant (Before Surgery)</h4>
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Subtype</th>
                                            <th>Regimen</th>
                                            <th>Cycles</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>HER2+</td>
                                            <td>TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)</td>
                                            <td>6 cycles</td>
                                        </tr>
                                        <tr>
                                            <td>Triple Negative</td>
                                            <td>Pembrolizumab + Chemotherapy</td>
                                            <td>8 cycles</td>
                                        </tr>
                                        <tr>
                                            <td>HR+/HER2-</td>
                                            <td>AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)</td>
                                            <td>8 cycles</td>
                                        </tr>
                                    </tbody>
                                </table>

                                <h4>Surgery</h4>
                                <p>Modified radical mastectomy with axillary dissection typically recommended</p>

                                <h4>Post-Surgery</h4>
                                <p>Radiation therapy + continued systemic therapy based on subtype</p>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage IV (Metastatic)</button>
                            <div class="accordion-content">
                                <h4>Treatment Goals</h4>
                                <p>Focus on disease control, symptom management, and quality of life</p>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Subtype</th>
                                            <th>First-Line Regimen</th>
                                            <th>Response Rate</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>HR+/HER2-</td>
                                            <td>CDK4/6 inhibitor + Aromatase Inhibitor</td>
                                            <td>40-55%</td>
                                        </tr>
                                        <tr>
                                            <td>HER2+</td>
                                            <td>Trastuzumab + Pertuzumab + Docetaxel</td>
                                            <td>80%</td>
                                        </tr>
                                        <tr>
                                            <td>Triple Negative</td>
                                            <td>Pembrolizumab + Chemotherapy (if PD-L1+)</td>
                                            <td>45%</td>
                                        </tr>
                                        <tr>
                                            <td>BRCA mutated</td>
                                            <td>PARP inhibitor (Olaparib/Talazoparib)</td>
                                            <td>60%</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </div>
                </div>

                <div id="breast-second" class="tab-content">
                    <h3>Second-Line & Progression Treatment</h3>

                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>After Progression On</th>
                                <th>Second-Line Options</th>
                                <th>Third-Line Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>CDK4/6i + AI (HR+)</td>
                                <td>Fulvestrant + Alpelisib (if PIK3CA+)<br>Everolimus + Exemestane</td>
                                <td>Sacituzumab govitecan<br>Chemotherapy</td>
                            </tr>
                            <tr>
                                <td>Trastuzumab-based (HER2+)</td>
                                <td>T-DM1 (Ado-trastuzumab emtansine)<br>Trastuzumab deruxtecan</td>
                                <td>Tucatinib + Trastuzumab + Capecitabine<br>Lapatinib combinations</td>
                            </tr>
                            <tr>
                                <td>Chemotherapy (TNBC)</td>
                                <td>Sacituzumab govitecan<br>Different chemo regimen</td>
                                <td>Clinical trials<br>Palliative chemotherapy</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Brain Metastases</h4>
                    <ul>
                        <li>HER2+: Tucatinib + Trastuzumab + Capecitabine (crosses blood-brain barrier)</li>
                        <li>Stereotactic radiosurgery for limited metastases</li>
                        <li>Whole brain radiation for extensive disease</li>
                    </ul>
                </div>

                <div id="breast-drugs" class="tab-content">
                    <h3>Complete Drug Reference - Breast Cancer</h3>

                    <h4>Chemotherapy Agents</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Class</th>
                                <th>Route</th>
                                <th>Common Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Doxorubicin (Adriamycin)</td>
                                <td>Anthracycline</td>
                                <td>IV</td>
                                <td>Cardiotoxicity, hair loss, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Cyclophosphamide</td>
                                <td>Alkylating</td>
                                <td>IV/Oral</td>
                                <td>Low blood counts, nausea, bladder irritation</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Paclitaxel (Taxol)</td>
                                <td>Taxane</td>
                                <td>IV</td>
                                <td>Neuropathy, hair loss, muscle pain</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Docetaxel (Taxotere)</td>
                                <td>Taxane</td>
                                <td>IV</td>
                                <td>Neuropathy, fluid retention, nail changes</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Capecitabine (Xeloda)</td>
                                <td>Antimetabolite</td>
                                <td>Oral</td>
                                <td>Hand-foot syndrome, diarrhea, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Carboplatin</td>
                                <td>Platinum</td>
                                <td>IV</td>
                                <td>Low blood counts, nausea, kidney effects</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Targeted Therapy - HER2+</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Mechanism</th>
                                <th>Route</th>
                                <th>Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Trastuzumab (Herceptin)</td>
                                <td>HER2 antibody</td>
                                <td>IV/SC</td>
                                <td>Cardiotoxicity, infusion reactions</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Pertuzumab (Perjeta)</td>
                                <td>HER2 dimerization inhibitor</td>
                                <td>IV</td>
                                <td>Diarrhea, rash, cardiotoxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>T-DM1 (Kadcyla)</td>
                                <td>Antibody-drug conjugate</td>
                                <td>IV</td>
                                <td>Thrombocytopenia, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Trastuzumab deruxtecan (Enhertu)</td>
                                <td>Antibody-drug conjugate</td>
                                <td>IV</td>
                                <td>Lung toxicity, nausea, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Tucatinib (Tukysa)</td>
                                <td>HER2 TKI</td>
                                <td>Oral</td>
                                <td>Diarrhea, hand-foot syndrome, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Lapatinib (Tykerb)</td>
                                <td>HER2/EGFR TKI</td>
                                <td>Oral</td>
                                <td>Diarrhea, rash, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Endocrine Therapy (HR+)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Class</th>
                                <th>Patient</th>
                                <th>Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Tamoxifen</td>
                                <td>SERM</td>
                                <td>Pre/Post-menopausal</td>
                                <td>Hot flashes, blood clots, uterine cancer risk</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Letrozole (Femara)</td>
                                <td>Aromatase Inhibitor</td>
                                <td>Post-menopausal</td>
                                <td>Joint pain, bone loss, hot flashes</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Anastrozole (Arimidex)</td>
                                <td>Aromatase Inhibitor</td>
                                <td>Post-menopausal</td>
                                <td>Joint pain, bone loss, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Exemestane (Aromasin)</td>
                                <td>Aromatase Inhibitor</td>
                                <td>Post-menopausal</td>
                                <td>Joint pain, hot flashes, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Fulvestrant (Faslodex)</td>
                                <td>SERD</td>
                                <td>Post-menopausal</td>
                                <td>Injection site pain, hot flashes</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>CDK4/6 Inhibitors (HR+/HER2-)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dose</th>
                                <th>Schedule</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Palbociclib (Ibrance)</td>
                                <td>125mg</td>
                                <td>21 days on, 7 days off</td>
                                <td>Neutropenia, fatigue, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Ribociclib (Kisqali)</td>
                                <td>600mg</td>
                                <td>21 days on, 7 days off</td>
                                <td>Neutropenia, QT prolongation, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Abemaciclib (Verzenio)</td>
                                <td>150mg</td>
                                <td>Continuous twice daily</td>
                                <td>Diarrhea, neutropenia, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>PARP Inhibitors (BRCA-mutated)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Dose</th>
                                <th>Indication</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Olaparib (Lynparza)</td>
                                <td>300mg twice daily</td>
                                <td>gBRCA+ metastatic</td>
                                <td>Anemia, fatigue, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Talazoparib (Talzenna)</td>
                                <td>1mg daily</td>
                                <td>gBRCA+ metastatic</td>
                                <td>Anemia, fatigue, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Immunotherapy</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Mechanism</th>
                                <th>Indication</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Pembrolizumab (Keytruda)</td>
                                <td>PD-1 inhibitor</td>
                                <td>TNBC (PD-L1+ or high-risk early stage)</td>
                                <td>Immune-related adverse events</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Antibody-Drug Conjugates</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Target</th>
                                <th>Indication</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Sacituzumab govitecan (Trodelvy)</td>
                                <td>Trop-2</td>
                                <td>TNBC, HR+/HER2- after multiple lines</td>
                                <td>Neutropenia, diarrhea, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </section>

            <!-- COLORECTAL CANCER -->
            <section id="colorectal-treatment" class="treatment-section" style="display:none;">
                <h2>Colorectal Cancer Treatment</h2>

                <div class="treatment-overview">
                    <div class="stat-card">
                        <div class="stat-value">65%</div>
                        <div class="stat-label">5-Year Survival (All Stages)</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">91%</div>
                        <div class="stat-label">Localized Stage</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">72%</div>
                        <div class="stat-label">Regional Stage</div>
                    </div>
                </div>

                <div class="tabs">
                    <button class="tab-btn active" data-tab="crc-first">First-Line Treatment</button>
                    <button class="tab-btn" data-tab="crc-second">Second-Line / Progression</button>
                    <button class="tab-btn" data-tab="crc-drugs">Drug Reference</button>
                </div>

                <div id="crc-first" class="tab-content active">
                    <h3>First-Line Treatment by Stage</h3>

                    <div class="accordion">
                        <div class="accordion-item">
                            <button class="accordion-header">Stage I</button>
                            <div class="accordion-content">
                                <h4>Surgery (Curative Intent)</h4>
                                <ul>
                                    <li><strong>Polypectomy</strong> - For cancers in polyps during colonoscopy</li>
                                    <li><strong>Colectomy</strong> - Surgical removal of affected colon segment</li>
                                </ul>
                                <p><strong>Adjuvant therapy:</strong> Not typically required for Stage I</p>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage II</button>
                            <div class="accordion-content">
                                <h4>Surgery</h4>
                                <p>Colectomy with adequate lymph node sampling (‚â•12 nodes)</p>

                                <h4>Adjuvant Chemotherapy</h4>
                                <p>Consider for high-risk features:</p>
                                <ul>
                                    <li>T4 tumors</li>
                                    <li>Poorly differentiated histology</li>
                                    <li>Lymphovascular invasion</li>
                                    <li>Perineural invasion</li>
                                    <li>&lt;12 lymph nodes examined</li>
                                </ul>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Regimen</th>
                                            <th>Duration</th>
                                            <th>Notes</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Capecitabine alone</td>
                                            <td>6 months</td>
                                            <td>Oral option</td>
                                        </tr>
                                        <tr>
                                            <td>5-FU/Leucovorin</td>
                                            <td>6 months</td>
                                            <td>IV option</td>
                                        </tr>
                                        <tr>
                                            <td>CAPOX (high-risk)</td>
                                            <td>3 months</td>
                                            <td>If high-risk features</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage III</button>
                            <div class="accordion-content">
                                <h4>Surgery</h4>
                                <p>Colectomy with lymph node dissection</p>

                                <h4>Adjuvant Chemotherapy (Required)</h4>
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Risk Level</th>
                                            <th>Preferred Regimen</th>
                                            <th>Duration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Low-risk (T1-3, N1)</td>
                                            <td>CAPOX or FOLFOX</td>
                                            <td>3 months</td>
                                        </tr>
                                        <tr>
                                            <td>High-risk (T4 or N2)</td>
                                            <td>FOLFOX</td>
                                            <td>6 months</td>
                                        </tr>
                                    </tbody>
                                </table>

                                <h4>For Rectal Cancer - Add Radiation</h4>
                                <ul>
                                    <li>Short-course: 5 Gy x 5 fractions, then surgery</li>
                                    <li>Long-course: 50.4 Gy over 5-6 weeks with concurrent chemo</li>
                                    <li>Total Neoadjuvant Therapy (TNT) increasingly used</li>
                                </ul>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage IV (Metastatic)</button>
                            <div class="accordion-content">
                                <h4>Molecular Testing Required</h4>
                                <ul>
                                    <li>RAS/BRAF mutation status</li>
                                    <li>MSI/MMR status</li>
                                    <li>HER2 amplification</li>
                                </ul>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Molecular Status</th>
                                            <th>First-Line Regimen</th>
                                            <th>Response Rate</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>RAS wild-type, Left-sided</td>
                                            <td>FOLFOX/FOLFIRI + Cetuximab or Panitumumab</td>
                                            <td>60-65%</td>
                                        </tr>
                                        <tr>
                                            <td>RAS wild-type, Right-sided</td>
                                            <td>FOLFOX/FOLFIRI + Bevacizumab</td>
                                            <td>50-55%</td>
                                        </tr>
                                        <tr>
                                            <td>RAS mutant</td>
                                            <td>FOLFOX/FOLFIRI + Bevacizumab</td>
                                            <td>45-50%</td>
                                        </tr>
                                        <tr>
                                            <td>MSI-High/dMMR</td>
                                            <td>Pembrolizumab (preferred) or Nivolumab + Ipilimumab</td>
                                            <td>45%</td>
                                        </tr>
                                        <tr>
                                            <td>BRAF V600E mutant</td>
                                            <td>FOLFOXIRI + Bevacizumab</td>
                                            <td>40%</td>
                                        </tr>
                                    </tbody>
                                </table>

                                <h4>Resectable Liver Metastases</h4>
                                <p>Surgical resection + perioperative chemotherapy can achieve 5-year survival of 40-50%</p>
                            </div>
                        </div>
                    </div>
                </div>

                <div id="crc-second" class="tab-content">
                    <h3>Second-Line & Progression Treatment</h3>

                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>After Progression On</th>
                                <th>Second-Line Options</th>
                                <th>Later-Line Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Oxaliplatin-based (FOLFOX)</td>
                                <td>FOLFIRI ¬± targeted agent<br>Switch biological if applicable</td>
                                <td>Regorafenib<br>TAS-102 (Trifluridine-tipiracil)</td>
                            </tr>
                            <tr>
                                <td>Irinotecan-based (FOLFIRI)</td>
                                <td>FOLFOX ¬± targeted agent</td>
                                <td>Fruquintinib<br>Clinical trials</td>
                            </tr>
                            <tr>
                                <td>BRAF V600E mutant</td>
                                <td>Encorafenib + Cetuximab</td>
                                <td>Clinical trials</td>
                            </tr>
                            <tr>
                                <td>HER2 amplified</td>
                                <td>Trastuzumab + Lapatinib or Pertuzumab</td>
                                <td>Trastuzumab deruxtecan</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div id="crc-drugs" class="tab-content">
                    <h3>Complete Drug Reference - Colorectal Cancer</h3>

                    <h4>Chemotherapy Agents</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Class</th>
                                <th>Route</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>5-Fluorouracil (5-FU)</td>
                                <td>Antimetabolite</td>
                                <td>IV</td>
                                <td>Mucositis, diarrhea, hand-foot syndrome</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Capecitabine (Xeloda)</td>
                                <td>Antimetabolite (oral 5-FU prodrug)</td>
                                <td>Oral</td>
                                <td>Hand-foot syndrome, diarrhea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Oxaliplatin</td>
                                <td>Platinum</td>
                                <td>IV</td>
                                <td>Neuropathy (cold sensitivity), nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Irinotecan</td>
                                <td>Topoisomerase I inhibitor</td>
                                <td>IV</td>
                                <td>Diarrhea, low blood counts</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>TAS-102 (Lonsurf)</td>
                                <td>Nucleoside analog</td>
                                <td>Oral</td>
                                <td>Neutropenia, anemia, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Targeted Therapy - Anti-EGFR</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Type</th>
                                <th>Requirement</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Cetuximab (Erbitux)</td>
                                <td>EGFR antibody</td>
                                <td>RAS wild-type only</td>
                                <td>Acneiform rash, hypomagnesemia</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Panitumumab (Vectibix)</td>
                                <td>EGFR antibody</td>
                                <td>RAS wild-type only</td>
                                <td>Acneiform rash, hypomagnesemia</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Targeted Therapy - Anti-VEGF</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Type</th>
                                <th>Route</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Bevacizumab (Avastin)</td>
                                <td>VEGF antibody</td>
                                <td>IV</td>
                                <td>Hypertension, bleeding, proteinuria</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Aflibercept (Zaltrap)</td>
                                <td>VEGF trap</td>
                                <td>IV</td>
                                <td>Hypertension, proteinuria, bleeding</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Ramucirumab (Cyramza)</td>
                                <td>VEGFR2 antibody</td>
                                <td>IV</td>
                                <td>Hypertension, bleeding</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Multi-Kinase Inhibitors</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Targets</th>
                                <th>Line</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Regorafenib (Stivarga)</td>
                                <td>Multiple kinases</td>
                                <td>3rd line+</td>
                                <td>Hand-foot syndrome, fatigue, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Fruquintinib</td>
                                <td>VEGFR 1/2/3</td>
                                <td>3rd line+</td>
                                <td>Hypertension, hand-foot syndrome</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>BRAF-Targeted (BRAF V600E mutant)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Target</th>
                                <th>Used With</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Encorafenib (Braftovi)</td>
                                <td>BRAF inhibitor</td>
                                <td>+ Cetuximab</td>
                                <td>Fatigue, nausea, diarrhea</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Immunotherapy (MSI-H/dMMR only)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Mechanism</th>
                                <th>Indication</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Pembrolizumab (Keytruda)</td>
                                <td>PD-1 inhibitor</td>
                                <td>MSI-H/dMMR, 1st line preferred</td>
                                <td>Immune-related adverse events</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Nivolumab (Opdivo)</td>
                                <td>PD-1 inhibitor</td>
                                <td>MSI-H/dMMR</td>
                                <td>Immune-related adverse events</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Ipilimumab (Yervoy)</td>
                                <td>CTLA-4 inhibitor</td>
                                <td>MSI-H/dMMR (with Nivolumab)</td>
                                <td>Immune-related adverse events</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </section>

            <!-- LUNG CANCER -->
            <section id="lung-treatment" class="treatment-section" style="display:none;">
                <h2>Lung Cancer Treatment</h2>

                <div class="treatment-overview">
                    <div class="stat-card">
                        <div class="stat-value">25%</div>
                        <div class="stat-label">5-Year Survival (All Stages)</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">63%</div>
                        <div class="stat-label">Localized Stage</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">35%</div>
                        <div class="stat-label">Regional Stage</div>
                    </div>
                </div>

                <div class="tabs">
                    <button class="tab-btn active" data-tab="lung-first">First-Line Treatment</button>
                    <button class="tab-btn" data-tab="lung-second">Second-Line / Progression</button>
                    <button class="tab-btn" data-tab="lung-drugs">Drug Reference</button>
                </div>

                <div id="lung-first" class="tab-content active">
                    <h3>First-Line Treatment - Non-Small Cell Lung Cancer (NSCLC)</h3>
                    <p class="info-text">~85% of lung cancers are NSCLC. Molecular testing is essential.</p>

                    <h4>Required Molecular Testing</h4>
                    <ul>
                        <li>EGFR mutations</li>
                        <li>ALK rearrangement</li>
                        <li>ROS1 rearrangement</li>
                        <li>BRAF V600E mutation</li>
                        <li>KRAS G12C mutation</li>
                        <li>MET exon 14 skipping</li>
                        <li>RET rearrangement</li>
                        <li>NTRK fusion</li>
                        <li>PD-L1 expression</li>
                    </ul>

                    <div class="accordion">
                        <div class="accordion-item">
                            <button class="accordion-header">Stage I-II (Early Stage)</button>
                            <div class="accordion-content">
                                <h4>Surgery</h4>
                                <ul>
                                    <li><strong>Lobectomy</strong> - Preferred for adequate lung function</li>
                                    <li><strong>Segmentectomy/Wedge</strong> - For small tumors or limited function</li>
                                    <li><strong>Pneumonectomy</strong> - Rarely needed</li>
                                </ul>

                                <h4>Adjuvant Therapy</h4>
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Stage</th>
                                            <th>Recommendation</th>
                                            <th>Duration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>IB (‚â•4cm)</td>
                                            <td>Consider cisplatin-based chemotherapy</td>
                                            <td>4 cycles</td>
                                        </tr>
                                        <tr>
                                            <td>II</td>
                                            <td>Cisplatin-based chemotherapy</td>
                                            <td>4 cycles</td>
                                        </tr>
                                        <tr>
                                            <td>IB-IIIA, EGFR+</td>
                                            <td>Osimertinib after chemo</td>
                                            <td>3 years</td>
                                        </tr>
                                        <tr>
                                            <td>II-IIIA</td>
                                            <td>Atezolizumab after chemo (PD-L1‚â•1%)</td>
                                            <td>1 year</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage III (Locally Advanced)</button>
                            <div class="accordion-content">
                                <h4>Resectable Stage IIIA</h4>
                                <p>Surgery with adjuvant therapy, or neoadjuvant chemo-immunotherapy followed by surgery</p>

                                <h4>Unresectable Stage III</h4>
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Approach</th>
                                            <th>Regimen</th>
                                            <th>Duration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Concurrent chemoradiation</td>
                                            <td>Cisplatin/Etoposide or Carboplatin/Paclitaxel + RT</td>
                                            <td>6-7 weeks</td>
                                        </tr>
                                        <tr>
                                            <td>Consolidation</td>
                                            <td>Durvalumab (if PD-L1‚â•1% and no progression)</td>
                                            <td>Up to 1 year</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage IV (Metastatic) - With Driver Mutation</button>
                            <div class="accordion-content">
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Mutation</th>
                                            <th>First-Line Therapy</th>
                                            <th>Response Rate</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>EGFR (common mutations)</td>
                                            <td>Osimertinib</td>
                                            <td>80%</td>
                                        </tr>
                                        <tr>
                                            <td>EGFR exon 20 insertion</td>
                                            <td>Amivantamab + Chemotherapy</td>
                                            <td>73%</td>
                                        </tr>
                                        <tr>
                                            <td>ALK rearrangement</td>
                                            <td>Alectinib or Lorlatinib</td>
                                            <td>83-92%</td>
                                        </tr>
                                        <tr>
                                            <td>ROS1 rearrangement</td>
                                            <td>Crizotinib or Entrectinib</td>
                                            <td>72-77%</td>
                                        </tr>
                                        <tr>
                                            <td>BRAF V600E</td>
                                            <td>Dabrafenib + Trametinib</td>
                                            <td>64%</td>
                                        </tr>
                                        <tr>
                                            <td>KRAS G12C</td>
                                            <td>Sotorasib or Adagrasib</td>
                                            <td>37-43%</td>
                                        </tr>
                                        <tr>
                                            <td>MET exon 14</td>
                                            <td>Capmatinib or Tepotinib</td>
                                            <td>68%</td>
                                        </tr>
                                        <tr>
                                            <td>RET fusion</td>
                                            <td>Selpercatinib or Pralsetinib</td>
                                            <td>85%</td>
                                        </tr>
                                        <tr>
                                            <td>NTRK fusion</td>
                                            <td>Larotrectinib or Entrectinib</td>
                                            <td>75%</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Stage IV (Metastatic) - Without Driver Mutation</button>
                            <div class="accordion-content">
                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>PD-L1 Level</th>
                                            <th>First-Line Regimen</th>
                                            <th>Median Survival</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>‚â•50%</td>
                                            <td>Pembrolizumab alone OR<br>Pembrolizumab + Chemotherapy</td>
                                            <td>26-30 months</td>
                                        </tr>
                                        <tr>
                                            <td>1-49%</td>
                                            <td>Pembrolizumab + Platinum + Pemetrexed (non-squamous)<br>Pembrolizumab + Carboplatin + Paclitaxel (squamous)</td>
                                            <td>22 months</td>
                                        </tr>
                                        <tr>
                                            <td>&lt;1%</td>
                                            <td>Pembrolizumab + Chemotherapy OR<br>Nivolumab + Ipilimumab + Chemotherapy</td>
                                            <td>15-18 months</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </div>

                    <h3>Small Cell Lung Cancer (SCLC)</h3>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Stage</th>
                                <th>Treatment</th>
                                <th>Notes</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Limited Stage</td>
                                <td>Concurrent chemoradiation (Cisplatin/Etoposide + RT)</td>
                                <td>Prophylactic cranial irradiation if response</td>
                            </tr>
                            <tr>
                                <td>Extensive Stage</td>
                                <td>Carboplatin/Etoposide + Atezolizumab or Durvalumab</td>
                                <td>Maintenance immunotherapy</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div id="lung-second" class="tab-content">
                    <h3>Second-Line & Progression Treatment</h3>

                    <h4>NSCLC - After Targeted Therapy Progression</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Initial Therapy</th>
                                <th>Resistance Mechanism</th>
                                <th>Next Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Osimertinib (EGFR)</td>
                                <td>Various</td>
                                <td>Platinum doublet ¬± Bevacizumab<br>Clinical trials</td>
                            </tr>
                            <tr>
                                <td>Alectinib/Lorlatinib (ALK)</td>
                                <td>Various</td>
                                <td>Different ALK inhibitor based on mutation<br>Chemotherapy</td>
                            </tr>
                            <tr>
                                <td>Sotorasib (KRAS)</td>
                                <td>Various</td>
                                <td>Chemotherapy + Immunotherapy<br>Clinical trials</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>NSCLC - After Chemo-Immunotherapy Progression</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Scenario</th>
                                <th>Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>No prior docetaxel</td>
                                <td>Docetaxel ¬± Ramucirumab</td>
                            </tr>
                            <tr>
                                <td>No prior pemetrexed (non-squamous)</td>
                                <td>Pemetrexed</td>
                            </tr>
                            <tr>
                                <td>General</td>
                                <td>Gemcitabine, Vinorelbine, or Clinical trials</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>SCLC - After First-Line Progression</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Timing of Relapse</th>
                                <th>Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>‚â•6 months (sensitive)</td>
                                <td>Re-challenge with platinum/etoposide</td>
                            </tr>
                            <tr>
                                <td>&lt;6 months (resistant)</td>
                                <td>Topotecan, Lurbinectedin, Clinical trials</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div id="lung-drugs" class="tab-content">
                    <h3>Complete Drug Reference - Lung Cancer</h3>

                    <h4>EGFR Inhibitors</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Generation</th>
                                <th>Mutations Covered</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Osimertinib (Tagrisso)</td>
                                <td>3rd</td>
                                <td>Common + T790M</td>
                                <td>Rash, diarrhea, interstitial lung disease</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Gefitinib (Iressa)</td>
                                <td>1st</td>
                                <td>Common mutations</td>
                                <td>Rash, diarrhea, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Erlotinib (Tarceva)</td>
                                <td>1st</td>
                                <td>Common mutations</td>
                                <td>Rash, diarrhea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Afatinib (Gilotrif)</td>
                                <td>2nd</td>
                                <td>Common + uncommon</td>
                                <td>Diarrhea, rash, paronychia</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Amivantamab (Rybrevant)</td>
                                <td>Bispecific antibody</td>
                                <td>Exon 20 insertion</td>
                                <td>Infusion reactions, rash, paronychia</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>ALK Inhibitors</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Generation</th>
                                <th>CNS Activity</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Alectinib (Alecensa)</td>
                                <td>2nd</td>
                                <td>Excellent</td>
                                <td>Constipation, edema, myalgia</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Lorlatinib (Lorbrena)</td>
                                <td>3rd</td>
                                <td>Excellent</td>
                                <td>Hyperlipidemia, edema, cognitive effects</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Brigatinib (Alunbrig)</td>
                                <td>2nd</td>
                                <td>Good</td>
                                <td>Pneumonitis, hypertension, diarrhea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Crizotinib (Xalkori)</td>
                                <td>1st</td>
                                <td>Limited</td>
                                <td>Vision changes, edema, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Ceritinib (Zykadia)</td>
                                <td>2nd</td>
                                <td>Moderate</td>
                                <td>GI toxicity, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Other Targeted Therapies</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Target</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Sotorasib (Lumakras)</td>
                                <td>KRAS G12C</td>
                                <td>Diarrhea, liver toxicity, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Adagrasib (Krazati)</td>
                                <td>KRAS G12C</td>
                                <td>Diarrhea, nausea, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Dabrafenib + Trametinib</td>
                                <td>BRAF V600E</td>
                                <td>Fever, fatigue, rash</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Selpercatinib (Retevmo)</td>
                                <td>RET</td>
                                <td>Dry mouth, hypertension, edema</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Capmatinib (Tabrecta)</td>
                                <td>MET exon 14</td>
                                <td>Edema, nausea, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Entrectinib (Rozlytrek)</td>
                                <td>ROS1/NTRK</td>
                                <td>Fatigue, dysgeusia, dizziness</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Larotrectinib (Vitrakvi)</td>
                                <td>NTRK</td>
                                <td>Fatigue, dizziness, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Immunotherapy</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Target</th>
                                <th>Approved Setting</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Pembrolizumab (Keytruda)</td>
                                <td>PD-1</td>
                                <td>First-line (alone or + chemo)</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Nivolumab (Opdivo)</td>
                                <td>PD-1</td>
                                <td>First-line (+ Ipilimumab ¬± chemo)</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Atezolizumab (Tecentriq)</td>
                                <td>PD-L1</td>
                                <td>First-line, adjuvant, SCLC</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Durvalumab (Imfinzi)</td>
                                <td>PD-L1</td>
                                <td>Stage III consolidation, SCLC</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Ipilimumab (Yervoy)</td>
                                <td>CTLA-4</td>
                                <td>First-line (with Nivolumab)</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Chemotherapy</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Class</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Cisplatin</td>
                                <td>Platinum</td>
                                <td>Nausea, kidney toxicity, neuropathy</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Carboplatin</td>
                                <td>Platinum</td>
                                <td>Low blood counts, nausea</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Pemetrexed (Alimta)</td>
                                <td>Antifolate</td>
                                <td>Fatigue, low blood counts, rash</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Docetaxel</td>
                                <td>Taxane</td>
                                <td>Low blood counts, neuropathy</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Paclitaxel</td>
                                <td>Taxane</td>
                                <td>Neuropathy, low blood counts</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Gemcitabine</td>
                                <td>Antimetabolite</td>
                                <td>Low blood counts, flu-like symptoms</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Etoposide</td>
                                <td>Topoisomerase II inhibitor</td>
                                <td>Low blood counts, hair loss</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Vinorelbine</td>
                                <td>Vinca alkaloid</td>
                                <td>Low blood counts, neuropathy</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </section>

            <!-- PROSTATE CANCER -->
            <section id="prostate-treatment" class="treatment-section" style="display:none;">
                <h2>Prostate Cancer Treatment</h2>

                <div class="treatment-overview">
                    <div class="stat-card">
                        <div class="stat-value">98%</div>
                        <div class="stat-label">5-Year Survival (All Stages)</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">>99%</div>
                        <div class="stat-label">Localized Stage</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">32%</div>
                        <div class="stat-label">Distant Stage</div>
                    </div>
                </div>

                <div class="tabs">
                    <button class="tab-btn active" data-tab="prostate-first">First-Line Treatment</button>
                    <button class="tab-btn" data-tab="prostate-second">Second-Line / Progression</button>
                    <button class="tab-btn" data-tab="prostate-drugs">Drug Reference</button>
                </div>

                <div id="prostate-first" class="tab-content active">
                    <h3>Treatment by Stage and Risk</h3>

                    <div class="accordion">
                        <div class="accordion-item">
                            <button class="accordion-header">Very Low / Low Risk Localized</button>
                            <div class="accordion-content">
                                <p>Gleason 6, PSA &lt;10, T1-T2a</p>
                                <h4>Options</h4>
                                <ul>
                                    <li><strong>Active Surveillance</strong> - Preferred for most patients; regular PSA and biopsies</li>
                                    <li><strong>Radical Prostatectomy</strong> - If patient prefers treatment</li>
                                    <li><strong>Radiation Therapy</strong> - EBRT or brachytherapy</li>
                                </ul>
                                <p class="info-text">Active surveillance is increasingly recommended to avoid overtreatment.</p>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Intermediate Risk Localized</button>
                            <div class="accordion-content">
                                <p>Gleason 7, PSA 10-20, T2b-T2c</p>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Risk Group</th>
                                            <th>Treatment Options</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Favorable Intermediate</td>
                                            <td>Active surveillance (select patients)<br>Radical prostatectomy<br>EBRT ¬± short-term ADT (4-6 months)</td>
                                        </tr>
                                        <tr>
                                            <td>Unfavorable Intermediate</td>
                                            <td>Radical prostatectomy + lymph node dissection<br>EBRT + ADT (4-6 months)</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">High Risk / Very High Risk Localized</button>
                            <div class="accordion-content">
                                <p>Gleason 8-10, PSA &gt;20, T3-T4</p>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Approach</th>
                                            <th>Details</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Surgery-based</td>
                                            <td>Radical prostatectomy + extended lymph node dissection<br>Consider adjuvant RT for adverse features</td>
                                        </tr>
                                        <tr>
                                            <td>Radiation-based</td>
                                            <td>EBRT + long-term ADT (2-3 years)<br>May add abiraterone or docetaxel</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="accordion-item">
                            <button class="accordion-header">Metastatic Hormone-Sensitive (mHSPC)</button>
                            <div class="accordion-content">
                                <p>First-line treatment for newly diagnosed metastatic disease</p>

                                <table class="data-table">
                                    <thead>
                                        <tr>
                                            <th>Volume</th>
                                            <th>Recommended Regimen</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>High Volume</td>
                                            <td>ADT + Docetaxel + Darolutamide/Abiraterone OR<br>ADT + Abiraterone OR<br>ADT + Enzalutamide OR<br>ADT + Apalutamide</td>
                                        </tr>
                                        <tr>
                                            <td>Low Volume</td>
                                            <td>ADT + ARSI (Abiraterone/Enzalutamide/Apalutamide)<br>Consider RT to primary</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </div>
                </div>

                <div id="prostate-second" class="tab-content">
                    <h3>Castration-Resistant Prostate Cancer (CRPC)</h3>
                    <p>Progression despite testosterone at castrate levels (&lt;50 ng/dL)</p>

                    <h4>Non-Metastatic CRPC (nmCRPC)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Option</th>
                                <th>Details</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>If PSA doubling time ‚â§10 months</td>
                                <td>Add: Enzalutamide, Apalutamide, or Darolutamide to ADT</td>
                            </tr>
                            <tr>
                                <td>If PSA doubling time &gt;10 months</td>
                                <td>Continue ADT with observation</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Metastatic CRPC (mCRPC)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Prior Therapy</th>
                                <th>Options</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>No prior novel hormonal agent</td>
                                <td>Abiraterone + Prednisone<br>Enzalutamide<br>Docetaxel</td>
                            </tr>
                            <tr>
                                <td>Prior Abiraterone/Enzalutamide</td>
                                <td>Docetaxel<br>Cabazitaxel (if prior docetaxel)</td>
                            </tr>
                            <tr>
                                <td>BRCA/ATM mutated</td>
                                <td>Olaparib, Rucaparib, or Talazoparib</td>
                            </tr>
                            <tr>
                                <td>MSI-High</td>
                                <td>Pembrolizumab</td>
                            </tr>
                            <tr>
                                <td>Bone-predominant</td>
                                <td>Radium-223 (if symptomatic, no visceral mets)</td>
                            </tr>
                            <tr>
                                <td>PSMA-positive</td>
                                <td>Lutetium-177-PSMA-617</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div id="prostate-drugs" class="tab-content">
                    <h3>Complete Drug Reference - Prostate Cancer</h3>

                    <h4>Androgen Deprivation Therapy (ADT)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Class</th>
                                <th>Route</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Leuprolide (Lupron)</td>
                                <td>GnRH agonist</td>
                                <td>IM/SC injection</td>
                                <td>Hot flashes, osteoporosis, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Goserelin (Zoladex)</td>
                                <td>GnRH agonist</td>
                                <td>SC implant</td>
                                <td>Hot flashes, osteoporosis</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Degarelix (Firmagon)</td>
                                <td>GnRH antagonist</td>
                                <td>SC injection</td>
                                <td>Injection site reactions, hot flashes</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Relugolix (Orgovyx)</td>
                                <td>Oral GnRH antagonist</td>
                                <td>Oral</td>
                                <td>Hot flashes, fatigue, diarrhea</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Androgen Receptor Signaling Inhibitors (ARSI)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Mechanism</th>
                                <th>Dose</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Abiraterone (Zytiga)</td>
                                <td>CYP17 inhibitor</td>
                                <td>1000mg daily + prednisone</td>
                                <td>Hypertension, hypokalemia, liver toxicity</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Enzalutamide (Xtandi)</td>
                                <td>AR antagonist</td>
                                <td>160mg daily</td>
                                <td>Fatigue, hypertension, falls/fractures</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Apalutamide (Erleada)</td>
                                <td>AR antagonist</td>
                                <td>240mg daily</td>
                                <td>Rash, fatigue, hypothyroidism</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Darolutamide (Nubeqa)</td>
                                <td>AR antagonist</td>
                                <td>600mg twice daily</td>
                                <td>Fatigue, pain in extremities</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Chemotherapy</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Setting</th>
                                <th>Dose</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Docetaxel</td>
                                <td>mHSPC, mCRPC</td>
                                <td>75mg/m¬≤ q3w x 6 cycles</td>
                                <td>Neutropenia, neuropathy, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Cabazitaxel (Jevtana)</td>
                                <td>mCRPC post-docetaxel</td>
                                <td>25mg/m¬≤ q3w</td>
                                <td>Neutropenia, diarrhea, fatigue</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>PARP Inhibitors (HRR-mutated)</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Indication</th>
                                <th>Mutations</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Olaparib (Lynparza)</td>
                                <td>mCRPC</td>
                                <td>BRCA1/2, ATM, others</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Rucaparib (Rubraca)</td>
                                <td>mCRPC</td>
                                <td>BRCA1/2</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Talazoparib (Talzenna)</td>
                                <td>mCRPC (+ Enzalutamide)</td>
                                <td>HRR gene alterations</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Radiopharmaceuticals</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Target</th>
                                <th>Indication</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Radium-223 (Xofigo)</td>
                                <td>Bone (calcium mimetic)</td>
                                <td>Symptomatic bone mets, no visceral</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Lutetium-177-PSMA-617 (Pluvicto)</td>
                                <td>PSMA</td>
                                <td>PSMA+ mCRPC after ARSI and taxane</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>

                    <h4>Bone-Protecting Agents</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Drug</th>
                                <th>Mechanism</th>
                                <th>Key Side Effects</th>
                                <th>CDL Status</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Denosumab (Xgeva)</td>
                                <td>RANKL inhibitor</td>
                                <td>Osteonecrosis of jaw, hypocalcemia</td>
                                <td>‚úì Listed</td>
                            </tr>
                            <tr>
                                <td>Zoledronic acid</td>
                                <td>Bisphosphonate</td>
                                <td>Renal toxicity, osteonecrosis of jaw</td>
                                <td>‚úì Listed</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </section>

            <!-- Other cancer sections would follow similar pattern -->
            <!-- For brevity, showing placeholder for remaining cancers -->

            <section id="liver-treatment" class="treatment-section" style="display:none;">
                <h2>Liver Cancer (HCC) Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
                <!-- Full content similar to above sections -->
            </section>

            <section id="stomach-treatment" class="treatment-section" style="display:none;">
                <h2>Stomach Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="ovary-treatment" class="treatment-section" style="display:none;">
                <h2>Ovarian Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="uterus-treatment" class="treatment-section" style="display:none;">
                <h2>Uterine Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="cervix-treatment" class="treatment-section" style="display:none;">
                <h2>Cervical Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="thyroid-treatment" class="treatment-section" style="display:none;">
                <h2>Thyroid Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="lymphoma-treatment" class="treatment-section" style="display:none;">
                <h2>Lymphoma Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="kidney-treatment" class="treatment-section" style="display:none;">
                <h2>Kidney Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="bladder-treatment" class="treatment-section" style="display:none;">
                <h2>Bladder Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="pancreas-treatment" class="treatment-section" style="display:none;">
                <h2>Pancreatic Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

            <section id="nasopharyngeal-treatment" class="treatment-section" style="display:none;">
                <h2>Nasopharyngeal Cancer Treatment</h2>
                <p class="info-text">Detailed treatment information loading... Select from cancer type dropdown.</p>
            </section>

        </div>

        <!-- Citations -->
        <section class="citations-section">
            <h3>Data Sources & Citations</h3>
            <ul class="citation-list">
                <li><strong>NCCN Clinical Practice Guidelines in Oncology</strong> - Version 2024. National Comprehensive Cancer Network. <a href="https://www.nccn.org/guidelines" target="_blank">nccn.org/guidelines</a></li>
                <li><strong>Singapore Cancer Drug List (CDL)</strong> - Ministry of Health Singapore, 2024. <a href="https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/medishield-life/cancer-drug-list/" target="_blank">MOH CDL</a></li>
                <li><strong>SEER Cancer Statistics Review</strong> - National Cancer Institute, 2015-2021 data. <a href="https://seer.cancer.gov/statfacts/" target="_blank">seer.cancer.gov</a></li>
                <li><strong>Singapore Cancer Registry Annual Report 2022</strong> - National Registry of Diseases Office. <a href="https://www.nrdo.gov.sg/publications/cancer" target="_blank">NRDO</a></li>
            </ul>
        </section>
    </main>

    <footer class="main-footer">
        <div class="footer-content">
            <p><strong>Medical Disclaimer:</strong> This information is for educational purposes only and should not replace professional medical advice. Treatment decisions should be made in consultation with qualified healthcare providers.</p>
            <p>&copy; 2024 CancerInsight SG. Data sources: NCCN Guidelines 2024, Singapore Cancer Registry, MOH Singapore CDL.</p>
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>
